<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01786239</url>
  </required_header>
  <id_info>
    <org_study_id>12-308B</org_study_id>
    <nct_id>NCT01786239</nct_id>
  </id_info>
  <brief_title>Omega-3 Dietary Supplements in Schizophrenia</brief_title>
  <official_title>Detecting Which Patients With Schizophrenia Will Improve With Omega-3 Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Delbert Robinson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Alliance for Research on Schizophrenia and Depression</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 16-week placebo-control study looks to investigate whether patients with schizophrenia
      for two years or less may benefit from omega-3 supplements.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study looks to investigate whether patients with schizophrenia for 2 years or less may
      benefit from omega-3 supplements. The main hypothesis to be tested in this study is that
      white matter integrity assessed with diffusion tensor imaging (DTI) and erythrocyte membrane
      omega-3 concentration may provide the means for identifying patients most likely to derive
      clinical benefit from omega-3 supplementation.

      To test this hypothesis the investigators will enroll 58 patients with recent-onset
      schizophrenia into a 16-week long randomized double blind placebo-controlled study of
      risperidone versus risperidone plus omega-3 supplementation. Study assessments after consent
      will include a baseline MRI and an MRI at the final visit, blood-work, clinical interviews to
      assess symptoms, and medical assessments for side effects. DTI exams and peripheral omega-3
      concentration will be obtained prior to the initiation of treatment and the primary outcome
      measure will be the total Brief Psychiatric Rating Scale Score.

      Specific aims are:

        -  To examine the efficacy of omega-3 fatty acids as an adjuvant agent in the treatment of
           patients with recent-onset schizophrenia. The investigators hypothesize that patients
           treated with omega-3 fatty acids will demonstrate greater Brief Psychiatric Rating Scale
           (BPRS) reductions compared to the placebo group.

        -  To identify whether pre-treatment fractional anisotropy (FA) assessed by DTI predicts
           which patients will derive clinical benefit from omega-3 fatty acids. The investigators
           hypothesize that patients with lower fractional anisotropy will derive greater clinical
           benefit from omega-3 fatty acid supplementation.

        -  To identify whether pre-treatment peripheral omega-3 fatty acid concentrations predict
           which patients will derive clinical benefit from omega-3 fatty acids. The investigators
           hypothesize that patients with lower peripheral omega-3 fatty acid concentrations will
           derive greater clinical benefit from omega-3 fatty acid supplementation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Response</measure>
    <time_frame>16 weeks</time_frame>
    <description>The primary outcome measure will be the total Brief Psychiatric Rating Scale Score. The range of the BPRS is 0 to 126 with higher scores indicated more psychological symptoms.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizophreniform Disorder</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Psychosis NOS</condition>
  <arm_group>
    <arm_group_label>Omega-3 capsules &amp; Risperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take 1 capsule in the morning and 1 capsule in the evening. Each capsule contains 370 mg EPA and 200 mg DHA as well as 2 mg/g tocopherol. The study dose will start on day 1 and remain the same throughout the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &amp; Risperidone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will take 1 capsule in the morning and 1 capsule in the evening.The placebo is a soybean/corn blend (each capsule contains 1000 mg). The study dose will start on day 1 and remain the same throughout the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.</description>
    <arm_group_label>Omega-3 capsules &amp; Risperidone</arm_group_label>
    <arm_group_label>Placebo &amp; Risperidone</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 capsules</intervention_name>
    <description>The total daily dose for omega-3 subjects will be 740 mg of eicosapentanoic acid (EPA)and 400 mg of docosahexaenoic acid(DHA). This dose will start on day 1 and stay the same dose until study completion.</description>
    <arm_group_label>Omega-3 capsules &amp; Risperidone</arm_group_label>
    <other_name>Omega-3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The total daily dose for subjects assigned to placebo will be 2000 mg. This dose will start on day 1 and stay the same dose until study completion.</description>
    <arm_group_label>Placebo &amp; Risperidone</arm_group_label>
    <other_name>Placebo capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current DSM-IV-defined diagnosis of schizophrenia, schizophreniform, schizoaffective
             disorder, psychosis NOS or Bipolar I as assessed using the Structured Clinical
             Interview for Axis I DSM-IV Disorders;

          -  Does not DSM-IV criteria for a current substance-induced psychotic disorder, a
             psychotic disorder due to a general medical condition, delusional disorder, brief
             psychotic disorder, shared psychotic disorder, or a mood disorder with psychotic
             features;

          -  current positive symptoms rated more than 4 (moderate) on one of these BPRS items:
             conceptual disorganization, grandiosity, hallucinatory behavior, and unusual thought
             content;

          -  is in a early phase of illness as defined by having taken antipsychotic medications
             for a cumulative lifetime period of 2 years or less;

          -  age 15 to 40;

          -  competent and willing to sign informed consent; and

          -  for women, negative pregnancy test and agreement to use a medically accepted birth
             control method.

        Exclusion Criteria:

          -  serious neurological or endocrine disorder or any medical condition or treatment known
             to affect the brain;

          -  any medical condition which requires treatment with a medication with psychotropic
             effects;

          -  significant risk of suicidal or homicidal behavior;

          -  cognitive or language limitations, or any other factor that would preclude subjects
             providing informed consent;

          -  medical contraindications to treatment with risperidone (e.g. neuroleptic malignant
             syndrome with prior risperidone exposure), omega-3 supplements (e.g. bleeding
             disorder, seafood allergies) or placebo capsules (e.g. allergies to capsule
             components);

          -  contraindications to MRI imaging (e.g. presence of a pacemaker);

          -  lack of response to a prior adequate trial of risperidone;

          -  taking omega-3 supplements within the past 8 weeks, and

          -  requires treatment with an antidepressant or mood stabilizing medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Delbert G Robinson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Zucker Hillside Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Zucker Hillside Hospital</name>
      <address>
        <city>Glen Oaks</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2013</study_first_submitted>
  <study_first_submitted_qc>February 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2013</study_first_posted>
  <results_first_submitted>September 12, 2016</results_first_submitted>
  <results_first_submitted_qc>January 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 1, 2017</results_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Delbert Robinson</investigator_full_name>
    <investigator_title>Psychiatrist</investigator_title>
  </responsible_party>
  <keyword>Adolescence</keyword>
  <keyword>Adult</keyword>
  <keyword>Antipsychotic Agents</keyword>
  <keyword>Female</keyword>
  <keyword>Human</keyword>
  <keyword>Male</keyword>
  <keyword>Risperidone</keyword>
  <keyword>Omega-3</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Schizophreniform</keyword>
  <keyword>Schizoaffective</keyword>
  <keyword>Schizophrenia -- *drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Omega-3 Capsules &amp; Risperidone</title>
          <description>Subjects will take 1 capsule in the morning and 1 capsule in the evening. Each capsule contains 370 mg EPA and 200 mg DHA as well as 2 mg/g tocopherol. The study dose will start on day 1 and remain the same throughout the study.
Risperidone: The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
Omega-3 capsules: The total daily dose for omega-3 subjects will be 740 mg of eicosapentanoic acid (EPA)and 400 mg of docosahexaenoic acid(DHA). This dose will start on day 1 and stay the same dose until study completion.</description>
        </group>
        <group group_id="P2">
          <title>Amber50/50 Soybean Corn Placebo &amp; Risperidone</title>
          <description>Subjects will take 1 capsule in the morning and 1 capsule in the evening.The placebo is a soybean/corn blend (each capsule contains 1000 mg). The study dose will start on day 1 and remain the same throughout the study.
Risperidone: The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
Amber 50/50 Soybean/Corn Placebo: The total daily dose for subjects assigned to placebo will be 2000 mg. This dose will start on day 1 and stay the same dose until study completion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Omega-3 Capsules &amp; Risperidone</title>
          <description>Subjects will take 1 capsule in the morning and 1 capsule in the evening. Each capsule contains 370 mg EPA and 200 mg DHA as well as 2 mg/g tocopherol. The study dose will start on day 1 and remain the same throughout the study.
Risperidone: The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
Omega-3 capsules: The total daily dose for omega-3 subjects will be 740 mg of eicosapentanoic acid (EPA)and 400 mg of docosahexaenoic acid(DHA). This dose will start on day 1 and stay the same dose until study completion.</description>
        </group>
        <group group_id="B2">
          <title>Placebo &amp; Risperidone</title>
          <description>Subjects will take 1 capsule in the morning and 1 capsule in the evening.The placebo is a soybean/corn blend (each capsule contains 1000 mg). The study dose will start on day 1 and remain the same throughout the study.
Risperidone: The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
Placebo: The total daily dose for subjects assigned to placebo will be 2000 mg. This dose will start on day 1 and stay the same dose until study completion.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Structured Clinical interview for DMS-IV (SCID)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Schizophreriform</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Schizophrenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bipolar 1 Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychosis NOS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Schizoaffective Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Response</title>
        <description>The primary outcome measure will be the total Brief Psychiatric Rating Scale Score. The range of the BPRS is 0 to 126 with higher scores indicated more psychological symptoms.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omega-3 Capsules &amp; Risperidone</title>
            <description>Subjects will take 1 capsule in the morning and 1 capsule in the evening. Each capsule contains 370 mg EPA and 200 mg DHA as well as 2 mg/g tocopherol. The study dose will start on day 1 and remain the same throughout the study.
Risperidone: The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
Omega-3 capsules: The total daily dose for omega-3 subjects will be 740 mg of eicosapentanoic acid (EPA)and 400 mg of docosahexaenoic acid(DHA). This dose will start on day 1 and stay the same dose until study completion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo &amp; Risperidone</title>
            <description>Subjects will take 1 capsule in the morning and 1 capsule in the evening.The placebo is a soybean/corn blend (each capsule contains 1000 mg). The study dose will start on day 1 and remain the same throughout the study.
Risperidone: The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
Placebo: The total daily dose for subjects assigned to placebo will be 2000 mg. This dose will start on day 1 and stay the same dose until study completion.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response</title>
          <description>The primary outcome measure will be the total Brief Psychiatric Rating Scale Score. The range of the BPRS is 0 to 126 with higher scores indicated more psychological symptoms.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline BPRS Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.64" spread="1.44"/>
                    <measurement group_id="O2" value="42.38" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 BPRS Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5868" spread="2.1744"/>
                    <measurement group_id="O2" value="27.2235" spread="2.4397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0493</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were assessed throughout the duration of the study. Typically these were assessed at each study visit starting at visit 1-through visits 16.Through study completion up to 16 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Omega-3 Capsules &amp; Risperidone</title>
          <description>Subjects will take 1 capsule in the morning and 1 capsule in the evening. Each capsule contains 370 mg EPA and 200 mg DHA as well as 2 mg/g tocopherol. The study dose will start on day 1 and remain the same throughout the study.
Risperidone: The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
Omega-3 capsules: The total daily dose for omega-3 subjects will be 740 mg of eicosapentanoic acid (EPA)and 400 mg of docosahexaenoic acid(DHA). This dose will start on day 1 and stay the same dose until study completion.</description>
        </group>
        <group group_id="E2">
          <title>Placebo &amp; Risperidone</title>
          <description>Subjects will take 1 capsule in the morning and 1 capsule in the evening.The placebo is a soybean/corn blend (each capsule contains 1000 mg). The study dose will start on day 1 and remain the same throughout the study.
Risperidone: The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
Placebo: The total daily dose for subjects assigned to placebo will be 2000 mg. This dose will start on day 1 and stay the same dose until study completion.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Delbert Robinson MD</name_or_title>
      <organization>Northwell Health</organization>
      <phone>7184708195</phone>
      <email>drobinso@northwell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

